Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2025-04-21 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司2024年度对会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (大信会计师事务所) for the year 2024, specifically regarding their audit work for 辰欣药业股份有限公司. It details the qualifications, independence, audit work plan, quality control, and resources of the auditor. It is not the audit report itself but an assessment of the auditor's performance and compliance with relevant laws and standards. The document length is 3551 characters, which is relatively short and focused on evaluation rather than presenting financial statements or audit results. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the document is best classified as AR. FY 2024
2025-04-21 Chinese
辰欣药业股份有限公司2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024 年度董事会工作报告' which translates to '2024 Annual Board of Directors Work Report'. It details the activities, meetings, and governance practices of the company's board of directors during the 2024 fiscal year. It includes information about shareholder meetings, board meetings, committee activities, independent directors' duties, governance improvements, insider trading controls, stock incentive plans, investor relations, and plans for 2025. The content is a comprehensive report on the board's work and governance rather than an announcement or a brief summary. It is not a full annual report (10-K) but specifically focuses on the board's activities and governance. Therefore, it fits best under the category 'Board/Management Information (MANG)', which covers announcements of changes or reports related to the company's board or senior management activities. The document length (6019 characters) and detailed content confirm it is a substantive report, not a mere announcement or certification. Hence, the classification is MANG with high confidence.
2025-04-21 Chinese
辰欣药业股份有限公司2024年度独立董事述职报告（王唯佳）
Board/Management Information Classification · 95% confidence The document is titled '2024年度独立董事述职报告' which translates to '2024 Annual Independent Director's Work Report'. It is a detailed report by an independent director of the company describing their duties, attendance at board meetings, communication with auditors, oversight of financial reports, internal controls, and other governance-related activities during the 2024 fiscal year. The content focuses on the independent director's role, compliance with laws and regulations, and corporate governance practices rather than presenting financial statements or audit results. It is not an annual report (10-K), audit report (AR), or management discussion and analysis (MDA). Instead, it fits best under Board/Management Information (MANG) as it relates to the independent director's report on their board duties and governance oversight. The document length is about 5450 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2025-04-21 Chinese
辰欣药业股份有限公司证券投资及金融衍生品交易管理制度（2025年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '证券投资与金融衍生品交易管理制度' (Securities Investment and Financial Derivatives Trading Management System) issued by 辰欣药业股份有限公司. It outlines the company's rules, principles, approval authorities, risk control, information disclosure, and legal responsibilities related to securities investment and derivatives trading. There is no indication that this is a financial report, earnings release, or regulatory filing announcing a report. It is a governance-related document detailing internal rules and procedures for managing securities and derivatives trading. Therefore, it fits best under Governance Information (CGR). The document length (4524 characters) and content support this classification with high confidence.
2025-04-21 Chinese
辰欣药业股份有限公司关于召开2024年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of the company 辰欣药业股份有限公司, including the date, voting methods, agenda items, and instructions for shareholders. It includes information about the meeting logistics, voting procedures, and proxy forms. The document does not contain the actual annual report or financial statements but rather the announcement and details for the upcoming AGM. The document length is 4246 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-21 Chinese
大信会计师事务所（特殊普通合伙）关于辰欣药业股份有限公司非经营性资金占用的专项报告
Regulatory Filings
2025-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.